Hint mode is switched on Switch off

Erasca, ordinary share
ERAS, US29479A1088

FIND, SAVE & TRACK INVESTMENTS WITH CBONDS WATCHLIST

With Cbonds Watchlist you can always stay updated on your investments to make conscious decisions!

Watchlist
You need to request access
Add a stock to WL
Choose all Reset all
Erasca, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Get access Watch full tour

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs ...
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers.
Show more Hide
  • Issuer
  • Full borrower / issuer name
    Erasca Inc
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ERAS
  • Placement
    16.07.2021
  • Lock up period
    180
  • Number of papers
    18,750,000
  • Volume of raised funds
    300 mln USD
  • Placement share
    16.14%
  • Final placement price
    16 USD
  • Price change since placement date
    -100%
  • By capitalization
    1,858.29 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ERAS
  • Placement
    09.12.2022
  • Lock up period
    180
  • Number of papers
    137,691,585
  • Volume of raised funds
    100 mln USD
  • Placement share
    11.17%
  • Final placement price
    6.5 USD
  • Price change since placement date
    187.77%
  • By capitalization
    895 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ERAS
  • Placement
    22.01.2026
  • Lock up period
    180
  • Number of papers
    22,500,000
  • Volume of raised funds
    225 mln USD
  • Placement share
    7.35%
  • Final placement price
    10 USD
  • Price change since placement date
    87.05%
  • By capitalization
    3,062.12 mln USD
Other placements of the issuer Hide

IFRS/US GAAP reports

2026
I q eng
II q eng
2025
I q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
II q eng
III q eng
IV q eng
Show more Hide

Related Stock indices

Indicators

News

10/08/2026 Erasca: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers
15/07/2026 Erasca Inc. (NASDAQ:ERAS) Stock Analysis: Clinical Progress, Price Target Hike, and Market Influences
27/04/2026 Erasca: Regulation Fd Disclosure, Other Events
29/01/2026 Erasca: Other Events
21/01/2026 Erasca: Other Events, Financial Statements And Exhibits
All organization news

Holders

Industry Leaders

Registration is required to get access.